Executive Summary
Apple successfully invalidated Omni MedSci’s wearable pulse‑oximeter patent in a final PTAB decision, finding all 23 claims unpatentable for obviousness. The Board affirmed claim constructions and applied the petitioner’s alternative argument on the combination of prior‑art references.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in SAMSUNG ELECTRONICS CO., LTD. et al. vs OMNI MEDSCI, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Yangtze Memory Technologies Company, Ltd. et al.vsMicron Technology, Inc. et al.
Micron successfully opposes Yangtze Memory’s request for Director Review of a PTAB decision denying institution of an IPR on its 3D NAND patent. The Board finds Yangtze’s arguments unsubstantiated and denies the review.
Apple Inc.vsHBCU Messaging US LP
Apple Inc. filed an IPR petition challenging all 30 claims of U.S. Patent 11,991,601, asserting that the claims are obvious over a combination of four prior‑art references covering wireless messaging. The petition seeks institution of the review and cancellation of the claims.
Ilooda Co., Ltd. et al.vsSerendia, LLC
Jeisys Medical Inc.'s IPR challenge against Serendia, LLC's '836 patent was instituted by the PTAB. The Board determined that the Petitioner's grounds of obviousness over prior art like Ganz were plausible and warranted further proceedings. This decision moves the dispute toward a trial phase in the medical device technology space.
Google LLC et al.vsHEADWATER RESEARCH LLC
The PTAB held that claims 1‑17, 19, 21‑27, 29 and 30 of Headwater Research’s ’733 patent are unpatentable. Google and Samsung successfully proved obviousness over the MMS 3GPP spec and the Ogawa encryption device.
BOE Technology Group Co., Ltd.vsSamsung Display Co., Ltd.
BOE Technology and Samsung Display filed a joint request asking the PTAB to keep their settlement agreement confidential and separate from the patent file, invoking statutory confidentiality provisions.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.